SGMT stock news

Sagimet Biosciences (NASDAQ: SGMT) Stock Skyrockets on Positive Denifanstat Trial Results

Shares of Sagimet Biosciences (NASDAQ: SGMT) skyrocketed 154% in the afternoon trading Monday following the release of positive topline results from Phase 2b FASCINATE-2 clinical trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH. Sagimet Biosciences (NASDAQ: SGMT) has shared some great […]

Sagimet Biosciences (NASDAQ: SGMT) Stock Skyrockets on Positive Denifanstat Trial Results Read More ยป